Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...
Investor's Business Daily on MSN8d
Viking Therapeutics Plunged 6% On Its Earnings Report. Here's Why.Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...
Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual agonist of the glucagon-like peptide 1 and glucose ...
The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735 ... Premium journey today. Viking Therapeutics (VKTX) Company Description: Viking ...
Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...
9don MSN
CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...
As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback